Enzymatics has launched version 3.0 of its Archer Analysis Pipeline. It's the latest incarnation of the company's next-generation sequence analysis platform for detecting and characterizing cancer-causing gene fusions and mutations from clinical samples.
Cancer diagnostic labs have started to test next-gen sequencing-based assays from two companies, Fusion Genomics and Enzymatics, to detect gene fusions as a complement and possible alternative to existing assays.
Reagent provider Enzymatics has commercialized a new targeted sequencing technology that allows customers to detect cancer-relevant gene fusions from RNA, and has plans to offer additional catalog and custom assays to study fusion transcripts as well as DNA variants.
NEW YORK (GenomeWeb News) – Following a Massachusetts court's decision not to rule on the merits of a case involving the alleged theft of intellectual property, New England Biolabs said on Wednesday that it plans to appeal the decision.